This treatment showed the key pathogenic features of NAFLD/NASH as enhanced steatosis, characterized by the upregulation of FASN and SCD1 and a concomitant reduction in β-oxidation-related pathways, as evidenced by a decreased expression of SIRT1 and PGC1α. This evidence concerns the gene SCD and metabolic dysfunction-associated steatotic liver disease.